ResMed has acquired Noctrix Health, a medical technology company specializing in wearable neuromodulation therapies for sleep and neurological conditions, for $340 million. This marks the first successful exit for Angelini Ventures, a corporate venture firm that invested in Noctrix during its $40 million Series C round in 2024. The acquisition will integrate Noctrix's FDA-authorized Nidra therapy for Restless Legs Syndrome into ResMed's broader sleep health ecosystem.

Despite the traditional 'Sell in May and Go Away' market pattern, 2026 shows strong potential for continued stock gains. With 84% of companies beating earnings expectations and 27% earnings growth, selective investing in fundamentally strong companies could outperform. The article highlights two healthcare stocks—DexCom and ResMed—as well-positioned to deliver significant upside potential despite trading below analyst price targets.

The global sleep apnea devices market is expected to grow at a CAGR of 7.05% from 2025 to 2034, driven by rising prevalence of sleep apnea affecting approximately 1 billion people worldwide, increased obesity rates, and technological innovations in CPAP, BiPAP, and oral appliances. Growth is further supported by expanding homecare and telemedicine adoption. However, challenges include high device costs, limited access in developing regions, and poor patient compliance with therapy.

The global respiratory care devices market is projected to grow from USD 24.3 billion in 2025 to USD 47.5 billion by 2034, at a CAGR of ~8%. Growth is driven by rising prevalence of chronic respiratory diseases (COPD, asthma, sleep apnea), increasing demand for home healthcare solutions, technological advancements, and post-COVID-19 awareness. North America leads with 41% market share, followed by Europe and Asia-Pacific.

ResMed, a leader in CPAP machines and respiratory care devices, presents an attractive investment opportunity with 11% year-over-year revenue growth, expanding digital health capabilities across 140+ countries, and a forward P/E ratio of 22 (below its five-year average of 29). However, investors should be aware of potential headwinds including uncertain Medicare reimbursement rates and emerging alternative treatments.

The global anti-snoring devices market is expected to grow from $1.81 billion in 2025 to $3.36 billion by 2033, with an 8.04% CAGR. Growth drivers include rising obesity rates, increased awareness of health risks associated with snoring, technological innovations, and improved e-commerce accessibility. Major players like Philips, ResMed, and SomnoMed are leading the market with advanced solutions.

ResMed reported strong Q2 FY2026 results with adjusted earnings of $2.81 beating consensus of $2.72, and sales of $1.42 billion up 11% YoY. The company received FDA clearance for its AI-enabled Smart Comfort device and expects high single-digit revenue growth with double-digit EPS growth. Most analysts maintain positive ratings despite competition concerns, though stock declined 2.33% on the day.

The global mechanical ventilators market is projected to grow from USD 4.04 billion in 2025 to USD 6.91 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by rising respiratory disease prevalence, expanding ICU infrastructure, and technological advancements including AI-enabled and portable ventilators. However, high device costs and limited healthcare funding remain significant market constraints.

The global sleep apnea devices market is projected to grow from USD 9.5 billion in 2024 to USD 15.8 billion by 2032, with a CAGR of approximately 6%. Growth is driven by rising OSA prevalence, technological advancements, increased awareness, and expanding healthcare infrastructure. North America leads the market with over 45% share, while Asia-Pacific emerges as a major growth driver. Key players include Philips, ResMed, and Fisher & Paykel Healthcare.

BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger in the eye surgery market.

The global sleep tech devices market is expected to grow from USD 17 billion in 2024 to USD 44 billion by 2032, driven by rising sleep disorder prevalence, increased awareness, and technological advancements. Wearables dominate with 69.69% revenue share, while North America leads regional growth. Key players include Philips, ResMed, Apple, Garmin, and Eight Sleep.

Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).